CBD's success in treating epilepsy raises hopes for depression, anxiety, PTSD, addiction, and autism
Building on CBD's proven anticonvulsant properties, a growing body of preclinical and clinical evidence suggests it may also help treat depression, anxiety, PTSD, addiction, and autism spectrum disorder.
Quick Facts
What This Study Found
Strong evidence supports CBD's anticonvulsant properties for epilepsy, and accumulating research suggests promising effects for depression, anxiety, PTSD, addiction, neurodegenerative disorders, and autism. The review highlights contributions from Brazilian researchers who pioneered CBD epilepsy research.
Key Numbers
CBD-based Epidiolex approved for Dravet's syndrome and Lennox-Gastaut syndrome; studies span depression, anxiety, PTSD, addiction, neurodegeneration, and autism
How They Did This
Narrative review of preclinical and clinical data on CBD for epilepsy and neuropsychiatric disorders, with historical context of Brazilian cannabinoid research.
Why This Research Matters
The FDA approval of CBD for epilepsy created a regulatory pathway that could be replicated for other neuropsychiatric conditions if clinical evidence continues to build.
The Bigger Picture
CBD's journey from folk medicine to FDA-approved epilepsy treatment represents a model for how other cannabinoid-based therapeutics might gain mainstream medical acceptance.
What This Study Doesn't Tell Us
Much evidence for non-epilepsy conditions remains preclinical. Clinical trials for neuropsychiatric indications are generally smaller and less rigorous than epilepsy trials. Optimal dosing for different conditions is unclear.
Questions This Raises
- ?Which neuropsychiatric condition has the strongest evidence for CBD efficacy beyond epilepsy?
- ?Will CBD need different formulations or doses for different psychiatric conditions?
Trust & Context
- Key Stat:
- CBD is FDA-approved for epilepsy with growing evidence for other neuropsychiatric uses
- Evidence Grade:
- Narrative review covering strong epilepsy evidence alongside preliminary data for other conditions
- Study Age:
- Published in 2021. Clinical trials for CBD in neuropsychiatric conditions continue to expand.
- Original Title:
- From an Alternative Medicine to a New Treatment for Refractory Epilepsies: Can Cannabidiol Follow the Same Path to Treat Neuropsychiatric Disorders?
- Published In:
- Frontiers in psychiatry, 12, 638032 (2021)
- Authors:
- Bitencourt, Rafael M, Takahashi, Reinaldo N(3), Carlini, Elisaldo A
- Database ID:
- RTHC-03003
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Could CBD treat mental health conditions beyond epilepsy?
Preclinical and early clinical evidence suggests CBD may have therapeutic potential for depression, anxiety, PTSD, addiction, and autism. However, the evidence is much stronger for epilepsy than for these other conditions.
How did CBD become an approved epilepsy treatment?
Early research in Brazil demonstrated CBD's anticonvulsant properties in animal models and small human trials. This eventually led to larger clinical trials and the 2018 FDA approval of Epidiolex for Dravet's syndrome and Lennox-Gastaut syndrome.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-03003APA
Bitencourt, Rafael M; Takahashi, Reinaldo N; Carlini, Elisaldo A. (2021). From an Alternative Medicine to a New Treatment for Refractory Epilepsies: Can Cannabidiol Follow the Same Path to Treat Neuropsychiatric Disorders?. Frontiers in psychiatry, 12, 638032. https://doi.org/10.3389/fpsyt.2021.638032
MLA
Bitencourt, Rafael M, et al. "From an Alternative Medicine to a New Treatment for Refractory Epilepsies: Can Cannabidiol Follow the Same Path to Treat Neuropsychiatric Disorders?." Frontiers in psychiatry, 2021. https://doi.org/10.3389/fpsyt.2021.638032
RethinkTHC
RethinkTHC Research Database. "From an Alternative Medicine to a New Treatment for Refracto..." RTHC-03003. Retrieved from https://rethinkthc.com/research/bitencourt-2021-from-an-alternative-medicine
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.